Wed, Apr 23, 2014, 3:07 AM EDT - U.S. Markets open in 6 hrs 23 mins

Recent

% | $
Quotes you view appear here for quick access.

Johnson & Johnson Message Board

  • kadaicher1 kadaicher1 Jul 23, 2013 3:50 PM Flag

    neurodegeneration

    JNJ was in partnership talks with this co some years back. They could be worth a punt with an Alzheimers trial also completing December this year. Upside is enormous.

    Prana Completes Phase 2 Huntington Disease Trial with PBT2
    Melbourne – July 23, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today
    announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with
    early to mid-stage Huntington disease. The Company expects to announce the results
    arising from the trial in October.
    Reach2HD is a randomised, double-blind, placebo-controlled Phase 2 trial testing the safety
    and efficacy of PBT2, the Company’s lead compound under development for both
    Huntington disease and Alzheimer’s disease.
    “We have been extremely pleased with the conduct of the trial, at all levels including
    recruitment and patient retention,” said Dr Ray Dorsey, Principal Investigator of the
    Reach2HD study and Director of the Huntington Study Group Coordination Center.
    Reach2HD had planned to recruit 100 patients with Huntington disease in 9 months. In fact,
    109 participants were enrolled in the trial within that period. “The strong rate of recruitment
    reflects support for the Reach2HD trial within the Huntington disease clinical research
    community,” said Dr Dorsey. Of the 109 enrolled, 104 patients completed the trial, reflecting
    a retention rate of over 95%.
    A Data Safety Monitoring Board met on five occasions throughout the trial and on each
    occasion recommended that no changes or modifications to the study protocol be made
    based on their review of the safety data.
    The primary outcome of the trial is safety and tolerability. The trial also includes a number of
    secondary outcome measures from the cognitive, motor and behavioural domains affected in
    Huntington disease. A positive result of Reach2HD will identify signals of therapeutic benefit
    in one or more of the domains measured, which will inform the design of the next clinical
    trial.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Prana finished the week on rising volume and a 20% rise over the last two days. Hard to get action like that on these big stocks. PRAN has broken out of its last trading range. Expect it to continue up to first trial results in October. I think perhaps JNJ could be going over the data they have from their last meetings in Aus a few years back.

      Sentiment: Buy

      • 1 Reply to kadaicher1
      • Prana have just hired a development manager. I guess they think at least one the trials are positive. Their Alzheimers trial completes in Dec with results expected in March next year.
        Their Huntington's trial is finished with results expected in less than 8 weeks.
        May be worth a small speculative punt. With a prospective AD drug the market cap of $117m is quite low.

        Sentiment: Buy

 
JNJ
100.18+0.18(+0.18%)Apr 22 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSTue, Apr 22, 2014 4:00 PM EDT
Allergan Inc.
NYSETue, Apr 22, 2014 4:00 PM EDT
GW Pharmaceuticals plc
NasdaqGMTue, Apr 22, 2014 4:00 PM EDT